MedVasc AB has appointed a new CEO and strengthened the board with a high-profile life science executive

As the next step in MedVasc's journey towards commercialization of the medical device Solutio™ in the US and European markets, the company has appointed Cathrin Johansson as new CEO and Eric Wahlberg as new Chair of the Board. MedVasc is an incubator company at SmiLe.

MedVasc´s founder, Dr Michael Åkesson, has developed and patented the medical device Solutio™, which is designed to minimize pain while maximizing both time and cost-efficiency in treatment of varicose veins. The results of a completed clinical study showed very positive results and now MedVasc is further strengthening the team.

"Cathrin Johansson's background, experience, and entrepreneurial mindset will contribute strongly to MedVasc's continued development where our next step is to start the regulatory process and prepare for commercialization in the US and the European market - I look forward to working together with Cathrin," says Michael Åkesson, founder and main owner, MedVasc.

Cathrin Johansson has diverse experience, working with startups, driving change, and establishing relevant collaborations both nationally and internationally. She has held several leading roles in both private and public organizations and most recently she worked with Ignite Sweden, where she has successfully contributed to catalyzing commercial collaborations between startups and large international corporations/public organizations. From September 1, she is heading the next steps in MedVasc's journey. 

In addition to appointing a new full-time CEO MedVasc AB has recently also appointed Eric Wahlberg as new Chair of the Board. Eric has 20 years of experience as a life science executive and advisor, including academic roles and as VP for early clinical development CV & GI at AstraZeneca and senior medical director for Allergan.

Photo: MedVasc´s CEO Cathrin Johansson and Chair of the Board Eric Wahlberg